Lantheus Medical Imaging parent Lantheus Holdings posted mixed results for its second quarter and first six months of 2019.
The company reported that a strong performance of its Definity ultrasound contrast agent was offset by lower revenue for its TechneLite radiopharmaceutical due to supplier challenges.
For the second quarter (end-June 30), Lantheus had worldwide revenues of $85.7 million, up 0.2% from $85.6 million in the second quarter of 2018. The company had second-quarter net income of $6.4 million, a decrease of 35.6% compared with net income of $9.7 million in the same quarter last year.
For the six-month period, the company posted revenues of $172.2 million, up from $168.2 million in the same period last year. Net income for the six months was $16.4 million, down from 2018's $18 million.
Definity second-quarter revenues were $53.5 million, an increase of 18.5% compared with $45.1 million in 2018. TechneLite revenues were $16.9 million, a decrease of 12.8% compared with $19.3 million last year. For the six-month period, Definity revenues were $103.2 million, an increase of 16.4% compared with $88.6 million in 2018, while TechneLite revenues were $36.9 million, down 1.3% from 2018's $37.4 million.
Lantheus expects third-quarter revenue to range between $83 million and $85 million, representing a growth rate range of 4.4% to 6.6%.
